Organization Overview
Historical Acquisition Tree
Alternative names
acalabrutinib (calquence) (2017 NDA)
acalabrutinib (calquence) (48 trials)
bendamustine (treanda) (5 trials)
Arthritis (Phase 2)
Arthritis, Rheumatoid (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Communicable Diseases (Phase 1)
Glioblastoma (Phase 2)
Hepatic Insufficiency (Phase 1)
Infections (Phase 1)
Leukemia (Phase 3)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)
Leukemia, Lymphoid (Phase 3)
Leukemia, Prolymphocytic (Phase 2)
Liver Diseases (Phase 1)
Liver Failure (Phase 1)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Mantle-Cell (Phase 3)
Lymphoma, Non-Hodgkin (Phase 1)
Multiple Myeloma (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Plasma Cell (Phase 1)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Syndrome (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)